ExonHit is a fast emerging healthcare player active in both therapeutics and diagnostics. ExonHit is based in Paris, France, and has US offices in Gaithersburg, Maryland. The Company employs 65 associates.
Board Member
Frederic was head of Pharma Equity Research and a partner at Exane BNP Paribas before joining Life Sciences consultancy Bionest Parters in 2005. He has headed a research team at GlaxoWellcome, been a Scientific Consultant for Hoechst and a Guest Investigator at NewYork’s Rockfeller University working on Alzheimer's Disease.
Frederic has a Ph.D. from the College de France (in collaboration with Rhône-Poulenc), an MSc in pharmacology and is a graduate of Ecole Polytechnique. He also belongs to the French Society of financial analysts (SFAF).